Loading...
Market
Story
Scholar Rock's Apitegromab Succeeds in Phase 3 SMA Trial with p=0.019, Stock Soars 200%
Oct 7, 2024, 12:01 PM
Scholar Rock announced that its drug apitegromab met the primary endpoint in a Phase 3 SAPPHIRE study for treating spinal muscular atrophy (SMA). The trial, which achieved statistical significance with a p-value of 0.019, demonstrated a clinically meaningful improvement in motor function among patients. As a result, Scholar Rock's stock soared more than 200%. The late-stage study involved patients already on standard-of-care treatments such as Spinraza and Risdiplam. The success of the trial positions Scholar Rock as a potential key player in the SMA treatment market.
View original story
Similar markets
Apitegromab • 25%
Evrysdi • 25%
Spinraza • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%